sNN0031
Sponsors
Newron Sweden AB
Conditions
Parkinson's Disease
Phase 1
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
CompletedNCT00866502
Start: 2009-03-31End: 2011-03-31Updated: 2015-01-12
A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
TerminatedNCT01829867
Start: 2013-04-30End: 2015-10-31Updated: 2016-01-27